Product Code: 596200402
How well does your Asthma/COPD medical affairs team compare with your rivals in the US?
Which brand's medical affairs team is perceived to be the best and which is the worst? Who scored almost 5 times better on the quality of overall interactions than the worst performers?
Find out how well your medical affairs team ranks and where physicians are still looking for improvements - specifically from your team and more generally. Get the report now.
Don't forget, if you also buy the EU5 version you'll get a free comparison report, saving you time understanding and analysing the differences uncovered between these crucial markets.
Packed with physician insight into seven of the leading asthma/COPD brands:
- Symbicort (Budesonide/Formoterol)
- Tudorza (Aclidinium)
- Boehringer Ingelheim
- Forest Laboratories
- Genentech / Novartis
- Advair (Fluticasone/Salmeterol)
- Anoro Ellipta (Umeclidinium/Vilanterol)
- Reputations vary considerably: There is a wide spread in how the individual teams are perceived in the important categories with some teams consistently highly rated
- Physicians think there's a solid performance: Areas of high importance score best overall
- Important areas scored higher: Medical affairs teams score more room for improvement in areas of lower importance
- Information needs score highest: Highest satisfaction is achieved around fulfilling information requirements
- US outperforming EU5: Physicians rate US medical affairs teams higher - with more scores for solid performance
- 1 brand lags behind: Who scored lowest on all important attributes?
Key issues explored
- The reputations of the medical affairs teams specialising in asthma/COPD evaluated using proprietary analysis and visualisation tools to show how the teams are perceived
- How medical affairs teams are being used by physicians and where they are seeking support
- How often physicians want contact with medical affairs teams
- What services from medical affairs teams are considered the most and least important
- Analysis of performance and where improvement is still needed across key categories, both overall and on a drug-by-drug basis
- A mix total of 100 pulmonologists (67) and general practitioners (33) across the US participated in this study
- Data was collected via a 15-minute internet-based questionnaire
Participants screened to ensure they:
- See at least 50 patients for asthma or COPD in a typical month
- Have been in active practice between 3-35 years
- Devote at least 50% of their time to direct patient care
- Have interacted with a medical affairs professional in the past 6 months for at least 1 of the listed products